Cerecor (CERC) Completes CERC-301 Phase 2 Enrollment in MDD
- Wall Street rises, buoyed by economic data; Dow sets high
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Amazon (AMZN) Could Open Over 2,000 Brick-and Mortar Groceries if Tests Succeed - DJ; Kroger (KR) on Watch
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- After-Hours Stock Movers 12/05: (TXMD) (COUP) (BOBE) Higher; (SB) (LXRX) (STWD) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Cerecor Inc. (NASDAQ: CERC) announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC-301, Clin301-203, as an oral, rapidly acting adjunctive treatment of major depressive disorder (“MDD”). The Company now expects to report top-line data from this trial in November 2016.
Cerecor launched its Phase 2 clinical trial with CERC-301 for the adjunctive treatment of MDD in September 2015. The randomized, double-blind, placebo-controlled trial enrolled 115 subjects with MDD who experienced a severe depressive episode despite stable ongoing treatment with either a serotonin reuptake inhibitor or a serotonin norepinephrine reuptake inhibitor. The trial includes two intermittent dose administrations seven days apart, followed by 14 days of observation. The primary objective of the trial is to evaluate the antidepressant effect of CERC-301 in 12 mg and 20 mg dosages compared to placebo as assessed by the six-item unidimensional subset of the Hamilton Depression Rating Scale.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerecor (CERC) Announces CERC-501 Phase 2 for Nicotine Withdrawal Missed Primary Endpoint
- Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal
- Two Neurocrine Biosciences (NBIX) INGREZZA Abstracts Will Be Presented at ACNP Meeting
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!